Addition of an IL-8-neutralizing antibody to SSc-IgG treated samples, as well as addition of NF-κB inactivator TPCK, significantly decreased neutrophil transendothelial migration (each P < 0.05, Figure 2B). Here, NFKB1 is linked to systemic sclerosis.